I have a little trouble believing this consulting firm’s rank-ordering of the biggest concentrations for biotech firms. Boston/Cambridge is at the top, and to be honest, I don’t think the list would be credible at all if it weren’t, by this point. But the number two slot is the Research Triangle area, and while I think it might be nice if that were true – I’ve lived in the area, and know a lot of people there – I don’t see how it is. The folks at FierceBiotech seem to have their doubts, too. Next is the SF Bay area, then San Diego, then New York, LA, and Philadelphia. (Note that New Jersey and Long Island get their own slots, which probably affect some of the rankings).
Anyone down in North Carolina want to make the case, for or against? I’d hope for GSK’s ferocious downsizing to create some new companies, but after all, it was a ferocious downsizing in any event. . .